Scholarlink

Objective <p>To assess the incidence of grade 3 or higher opportunistic pneumonia or drug-induced interstitial lung disease (DILD) during the treatment of patients with advanced&#xa0;RET fusion-positive (RET&#xa0;+) non-small-cell lung cancer (NSCLC) using pralsetinib.</p> Methods <p>A retrospective analysis was conducted on the clinical data of 44 patients with advanced RET + NSCLC treated at Chinese PLA General Hospital from March 2017 to October 2023. Patients were divided into a severe pneumonia group and a control group using propensity score matching, and differences in efficacy, survival, and prognostic factors were compared between the two groups.</p> Results <p>Nine patients were in the severe pneumonia group and 35 in the control group. The objective response rate (ORR) for RET + NSCLC patients was 50%, and for the severe pneumonia group, 62.5%. There was no significant difference in the median progression-free survival (PFS) and overall survival (OS) between the two groups. An ECOG score of ≥ 2 was an important prognostic factor affecting OS (HR = 4.55, <i>P</i> = 0.016), while the impact of severe infectious pneumonia did not reach statistical significance.</p> Conclusions <p>These findings provide new insights into the individualized treatment of RET&#xa0;+&#xa0;NSCLC patients and emphasize the importance of considering the overall health status of patients in treatment decisions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Grade 3 and above opportunistic pneumonia or drug-induced interstitial lung disease during tyrosine-kinase inhibitor treatment for advanced non-small-cell lung cancer with RET fusion mutations: coexistence of risks and opportunities

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月12日

查看全文
  • An Wang,
  • Tao Li,
  • Yun-ye Mao,
  • Xiaoran Cui,
  • Chang Liu,
  • Min Liu,
  • Lu Yu,
  • Fan Yang,
  • Yi Dong,
  • Ruixin Li,
  • Fan Zhang,
  • Tong Zhang,
  • Yi Hu

摘要

Objective

To assess the incidence of grade 3 or higher opportunistic pneumonia or drug-induced interstitial lung disease (DILD) during the treatment of patients with advanced RET fusion-positive (RET +) non-small-cell lung cancer (NSCLC) using pralsetinib.

Methods

A retrospective analysis was conducted on the clinical data of 44 patients with advanced RET + NSCLC treated at Chinese PLA General Hospital from March 2017 to October 2023. Patients were divided into a severe pneumonia group and a control group using propensity score matching, and differences in efficacy, survival, and prognostic factors were compared between the two groups.

Results

Nine patients were in the severe pneumonia group and 35 in the control group. The objective response rate (ORR) for RET + NSCLC patients was 50%, and for the severe pneumonia group, 62.5%. There was no significant difference in the median progression-free survival (PFS) and overall survival (OS) between the two groups. An ECOG score of ≥ 2 was an important prognostic factor affecting OS (HR = 4.55, P = 0.016), while the impact of severe infectious pneumonia did not reach statistical significance.

Conclusions

These findings provide new insights into the individualized treatment of RET + NSCLC patients and emphasize the importance of considering the overall health status of patients in treatment decisions.